News

Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Sartorius Stedim Biotech SA / Key word (s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST ...
‘I think it is actively happening’: Is Boston’s biotech industry doomed?
With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...
Seeking Alpha28d
Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
I believe that a good speculative biotech ... [In other words, it's rare for patients who don't smoke to get it, but can still get it]. It is important to note that there are two certain types ...
Knightscope Secures $1.2+ Million Boost in Sales Won and Client Base Growth
Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, ...
Business Insider10d
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi , CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at ...
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP ...
PharmiWeb2d
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
PharmiWeb3d
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
TMCnet1d
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Foralumab is the first fully human anti-CD3 monoclonal antibody administered via the intranasal route. This novel, non-systemic approach is designed to engage regulatory T cells, promoting immune ...
The Print on MSN12d
The tag of being India’s 1st ever ‘indigenous’ MRI machine has 2 contenders. There is no true winner
One MRI machine, built by a Bengaluru startup, is CDSCO-approved, but stuck at an unfinished hospital. The other, developed ...
The Word That Took Over Wall Street — and What It Means for Your Portfolio
In 1812, the English word unprecedented doubled in use, according to Google’s “Ngram” study of historical books. America’s war with Great Britain had just begun… Napoleon’s Grand Army invaded ...
The Manila Times1d
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and ...